Citigroup
BDTX icon

Citigroup’s Black Diamond Therapeutics BDTX Stock Holding History

Citigroup’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8K Buy
23,136
+21,544
+1,353% +$52.7K ﹤0.01% 5014
2026
Q1 		$3.39K Sell
1,592
-22,442
-93% -$53.4K ﹤0.01% 5346
2025
Q4 		$58.4K Buy
24,034
+23,123
+2,538% +$81.9K ﹤0.01% 4518
2025
Q3 		$3.45K Sell
911
-30,903
-97% -$90.4K ﹤0.01% 5343
2025
Q2 		$78.9K Buy
31,814
+1,848
+6% +$3.56K ﹤0.01% 4529
2025
Q1 		$46.4K Sell
29,966
-1,503
-5% -$3.15K ﹤0.01% 4883
2024
Q4 		$67.3K Buy
31,469
+2,664
+9% +$7.63K ﹤0.01% 4996
2024
Q3 		$125K Buy
28,805
+20,642
+253% +$112K ﹤0.01% 4653
2024
Q2 		$38K Sell
8,163
-104,288
-93% -$560K ﹤0.01% 4736
2024
Q1 		$570K Buy
112,451
+58,327
+108% +$235K ﹤0.01% 3473
2023
Q4 		$152K Sell
54,124
-7,224
-12% -$16.9K ﹤0.01% 4043
2023
Q3 		$176K Buy
+61,348
New +$226K ﹤0.01% 3718
2023
Q1 		– Sell
-135
Closed -$243 – 5504
2022
Q4 		$243 Sell
135
-438
-76% -$789 ﹤0.01% 5579
2022
Q3 		$1K Sell
573
-481
-46% -$1.48K ﹤0.01% 5604
2022
Q2 		$3K Sell
1,054
-908
-46% -$2.11K ﹤0.01% 5762
2022
Q1 		$5K Sell
1,962
-4,934
-72% -$18K ﹤0.01% 5796
2021
Q4 		$37K Sell
6,896
-42,002
-86% -$293K ﹤0.01% 5200
2021
Q3 		$414K Sell
48,898
-7,302
-13% -$72.1K ﹤0.01% 3740
2021
Q2 		$685K Sell
56,200
-71,691
-56% -$1.42M ﹤0.01% 3482
2021
Q1 		$3.1M Buy
127,891
+120,421
+1,612% +$3.25M ﹤0.01% 2177
2020
Q4 		$239K Buy
7,470
+4,614
+162% +$152K ﹤0.01% 4859
2020
Q3 		$86K Sell
2,856
-1,133
-28% -$34.5K ﹤0.01% 5227
2020
Q2 		$169K Buy
3,989
+452
+13% +$16.6K ﹤0.01% 5151
2020
Q1 		$88K Buy
+3,537
New +$108K ﹤0.01% 5447

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citigroup's BDTX Position: Q2 2026 in Review

Citigroup increased its Black Diamond Therapeutics (BDTX) stake by 1,353% in Q2 2026, buying an estimated $52.7K and bringing the position to 23,136 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5014.

Citigroup first reported a position in BDTX in Q1 2020 and has held it in 24 quarters since. The position peaked at $3.1M in Q1 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Citigroup held 23,136 shares of Black Diamond Therapeutics worth $42.8K as of Q2 2026.
  • Citigroup bought 21,544 Black Diamond Therapeutics shares in Q2 2026, an estimated $52.7K.
  • Black Diamond Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5014 holding.
  • Citigroup first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Citigroup's Black Diamond Therapeutics position peaked at $3.1M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.